Clinical Trial Update: Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for avelumab in combination with bempegaldesleukin with or without talazoparib or enzalutamide in advanced solid tumors (Phase 1/2); study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• Avelumab (avelumab)
• Bempegaldesleukin (bempegaldesleukin)
• Enzalutamide (enzalutamide)
• Talazoparib (talazoparib)

Snippet

Sponsor: Pfizer | Conditions: Squamous Cell Carcinoma of the Head and Neck (SCCHN), Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2021-10-14